DDInter1722 DDInter1840
A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Sulfadoxine {u} (Compound) resembles {v} (Compound) Sulfamethizole
Sulfamethizole {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Trabectedin
Sulfadoxine {u} (Compound) resembles {v} (Compound) Sulfaphenazole
Sulfaphenazole {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Trabectedin
Sulfadoxine {u} (Compound) resembles {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Sulfadoxine {u} (Compound) upregulates {v} (Gene) PAK1
PAK1 {u} (Gene) covaries with {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Trabectedin
Sulfadoxine {u} (Compound) upregulates {v} (Gene) PLSCR1
PLSCR1 {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Sulfadoxine {u} (Compound) resembles {v} (Compound) Sulfadiazine
Sulfadiazine {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Sulfadoxine {u} (Compound) upregulates {v} (Gene) FAS
FAS {u} (Gene) interacts with {v} (Gene) and {u} (Gene) regulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Sulfadoxine {u} (Compound) downregulates {v} (Gene) SLC5A6
SLC5A6 {u} (Gene) regulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Sulfadoxine {u} (Compound) downregulates {v} (Gene) FAM57A
FAM57A {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Sulfadoxine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naltrexone
Naltrexone {u} (Compound) causes {v} (Side Effect) Dyspnoea
Dyspnoea {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Sulfadoxine (Compound) resembles Sulfamethizole (Compound) and Sulfamethizole (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Trabectedin (Compound)
Sulfadoxine (Compound) resembles Sulfaphenazole (Compound) and Sulfaphenazole (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Trabectedin (Compound)
Sulfadoxine (Compound) resembles Sulfamethoxazole (Compound) and Sulfamethoxazole (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Trabectedin (Compound)
Sulfadoxine (Compound) upregulates PAK1 (Gene) and PAK1 (Gene) covaries with CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Trabectedin (Compound)
Sulfadoxine (Compound) upregulates PLSCR1 (Gene) and PLSCR1 (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Sulfadoxine (Compound) resembles Sulfadiazine (Compound) and Sulfadiazine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Trabectedin (Compound)
Sulfadoxine (Compound) upregulates FAS (Gene) and FAS (Gene) interacts with SRC (Gene) and FAS (Gene) regulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Sulfadoxine (Compound) downregulates SLC5A6 (Gene) and SLC5A6 (Gene) regulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Sulfadoxine (Compound) downregulates FAM57A (Gene) and FAM57A (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Sulfadoxine may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Trabectedin (Compound)